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Background: Men with screen-detected prostate cancer can choose to undergo immediate curative treatment or enter into an
expectant management programme. We quantified how the benefits and harms of immediate treatment vary according
to the prognostic factors of clinical T-stage, Gleason score, and patient age.
Methods: A microsimulation model based on European Randomized Study of Screening for Prostate Cancer data was used to
predict the benefits and harms of immediate treatment versus delayed treatment of local–regional prostate cancer in men aged
55–74 years. Benefits included life-years gained and reduced probability of death from prostate cancer. Harms included lead time
and probability of overdiagnosis.
Results: The ratio of mean lead time to mean life-years gained ranged from 1.8 to 31.2, and the additional number of treatments
required per prostate cancer death prevented ranged from 0.3 to 11.6 across the different prognostic groups. Both harm–benefit
ratios were lowest, most favourable, for men aged 55–59 years and diagnosed with moderate-risk prostate cancer. Ratios were
high for men aged 70–74 years regardless of clinical T-stage and Gleason score.
Conclusion: Men aged 55–59 years with moderate-risk prostate cancer are predicted to derive greatest benefit from
immediate curative treatment. Immediate treatment is least favourable for men aged 70–74 years with either low-risk or
high-risk prostate cancer.
The European Randomized Study of Screening for Prostate Cancer
(ERSPC) and the Gothenburg trial (part of the ERSPC) have
shown that a reduction in prostate cancer mortality can be
achieved using prostate-specific antigen (PSA) screening (Schroder
et al, 2009; Hugosson et al, 2010; Schroder et al, 2012). It has been
shown that after adjusting for quality of life there is still a
substantial benefit (Heijnsdijk et al, 2012).
Men with screen-detected prostate cancer can choose between
receiving immediate active treatment or entering into an expectant
management programme. The potential benefit of actively treating
the cancer immediately after diagnosis is an increase in life
expectancy. The potential harm is the risk of living for many years
with the side effects of treatment, years which might otherwise
have been symptom free (Korfage et al, 2005). Alternatively, the
potential benefit can be expressed as the reduction of prostate
cancer-specific mortality, and the potential harm expressed as the
percentage of overdiagnosis, that is, the proportion of men with
screen-detected prostate cancer that, in the absence of screening,
would die from other causes before the time of clinical diagnosis.
The aim of the present study was to quantify the potential
benefits and harms of immediate versus delayed active treatment
for local–regional prostate cancer according to the following
factors at time of detection: clinical T-stage, Gleason score, and
patient age. The results presented in this study are intended to help
clinicians and patients decide whether or not treatment is
favourable immediately after early detection.
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MATERIALS AND METHODS
ERSPC trial: Rotterdam and Gothenburg sections. The ERSPC
trial was initiated in the early 1990s in order to evaluate the effect
of PSA screening on prostate cancer mortality. In the Rotterdam
and Gothenburg sections, 42 376 men aged 55–74 years and 19 946
men aged 50–64 years were randomised, respectively. The time
interval between the screening rounds was 4 years in Rotterdam
and 2 years in Gothenburg. An overall reduction in prostate cancer
mortality of 29% at a median follow-up of 11 years was observed in
the ERSPC (Schroder et al, 2012).
MISCAN model. We used the MIcrosimulation SCreening
Analysis (MISCAN) prostate cancer model (Draisma et al, 2003,
2006, 2009; Wever et al, 2010a). MIcrosimulation SCreening
ANalysis is a microsimulation programme that simulates progres-
sion and screening of prostate cancer within a population. The
model was validated using prostate cancer detection data from the
Rotterdam (Draisma et al, 2003, 2006; Wever et al, 2010a) and
Gothenburg (Hugosson et al, 2004) sections of the ERSPC, as
well as the mortality reduction data from the overall ERSPC trial
(Schroder et al, 2012). A summary of the assumptions in the model
and the data used for calibration are presented in Table 1 and
are outlined below. A more detailed description of the model can
be found in earlier publications (Draisma et al, 2003, 2006) and in
a standardised model profile (Wever et al, 2010b).
MIcrosimulation SCreening ANalysis is a microsimulation
programme, which simulates the progression of prostate cancer
in individuals as a sequence of preclinical, clinical, and screen-
detected tumour states. First, the age at death from other causes is
simulated per individual using Dutch life tables (Statistics Nether-
lands, 2000–2007). Next, the progression of prostate cancer in the
absence of screening is simulated. Prostate cancer may develop
from no prostate cancer to a clinically diagnosed cancer through
one or more screen-detectable preclinical stages. From each
preclinical stage, a tumour may grow to the next clinical T-stage
(T1, impalpable; T2, palpable, confined to the prostate; T3þ ,
palpable, with extensions beyond the prostatic capsule); it may
dedifferentiate to a higher Gleason score (well differentiated,
Gleason score 2–6; moderately differentiated, Gleason score 7;
poorly differentiated, Gleason score 8–10); or it may be clinically
diagnosed. For these transitions, the time spent in the current stage
is generated from a Weibull distribution, where the parameters
depend on the current stage and the choice of next stage is
determined by transition probabilities. In addition, there is a risk
that a tumour in the local–regional stage (M0) will develop
into distant disease (M1), which is modelled by using a stage and
Gleason score-specific hazard function. Depending on the
frequency and sensitivity of the screening test, preclinical cancers
may be detected by screening. PSA test and subsequent biopsy
were modelled as a single test, where the sensitivity parameter was
assumed to be clinical T-stage-dependent. In the model, sensitivity
is defined as the probability that a preclinical tumour is detected by
a screening test at the time the test is taken.
Model parameters, including transition probabilities, mean
dwelling times (the time from one preclinical state to another
preclinical or clinical state), and stage-specific test sensitivities were
estimated by constructing models for the ERSPC-Rotterdam and
-Gothenburg, and by calibrating the model to the following data
observed at these centres: baseline incidence (national cancer
registry data for 1991 (Visser et al, 1994)) and stage distribution in
the Netherlands (Rotterdam cancer registry data 1992–1993
(Spapen et al, 2000)); baseline incidence in Sweden (1988–1992
(Parkin et al, 1997)); incidence, Gleason and stage distributions in
the control arms of ERSPC-Rotterdam and -Gothenburg; and
detection rates, interval cancer rates, Gleason and stage distribu-
tions in the screen arms of ERSPC-Rotterdam (Draisma et al, 2003,
2006; Wever et al, 2010a) and Gothenburg (Hugosson et al, 2004).
Number of cases diagnosed, and Gleason and stage distributions in
the control arms versus those in the screen arms provide insight
into disease progression through the various preclinical phases.
Parameters were estimated by numerically minimising the
deviance between the number of cases observed and the number
of cases predicted by the models. Deviances were calculated by
assuming Poisson likelihood for incidence data and by assuming
multinomial likelihood for stage-distribution data.
Survival after clinical diagnosis of untreated prostate cancer was
assumed to be according to the Gleason score-specific survival
curves of (Albertsen et al, 2005), but we added clinical T-stage as
an explanatory factor. For this, we used the Cox proportional
hazard estimates from (Aus et al, 2005; T1 1, T2 1.51, T3 2.77), and
Table 1. Modelling assumptions and data used in the present study
Variable Assumption Calibration data
Other cause of death Life tables Statistics Netherlands, 2000–2007
Disease progression before diagnosis Semi-Markov model National Cancer Registry data, 1991
(Visser et al, 1994)
Rotterdam Cancer Registry data, 1992–1993
(Spapen et al, 2000)
Incidence in Sweden, 1988–1992 (Parkin
et al, 1997)
ERSPC Rotterdam trial (Draisma et al, 2003;
Wever et al, 2010a)
ERSPC Gothenburg trial (Hugosson et al, 2004)
Baseline prostate cancer-specific survival
dependent on Gleason score
Poisson regression model Connecticut Tumor Registry data
(Albertsen et al, 2005)
Baseline prostate cancer-specific survival
dependent on clinical T-stage
Relative risk compared with baseline survival dependent
on Gleason score
Population-based National Prostate Cancer
Registry of Sweden (Aus et al, 2005)
Treatment effect Relative risk compared with baseline survival SPCG-4 study (Bill-Axelson et al, 2011)
Screening effect A proportion of men with screen-detected prostate
cancer are cured when treated early
ERSPC trial (Schroder et al, 2012)
Abbreviations: ERSPC¼European Randomized Study of Screening for Prostate Cancer; SPCG¼Scandinavian Prostate Cancer Group.
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changed the Albertsen model such that the weighted sum of
hazards by clinical T-stage add up to the same overall level by
age and Gleason score.
In the model, we assumed that all men diagnosed with prostate
cancer receive radical prostatectomy. According to published
results, (Bill-Axelson et al, 2011), we assumed that men receiving
radical prostatectomy have a relative risk of 0.62 of dying from
prostate cancer compared with men receiving no initial treatment.
This analysis did not consider other treatments, such as radiation
therapy and active surveillance, because of the limited published
results about the effectiveness of these treatments. If the
effectiveness of radiation therapy and active surveillance are
different than that of radical prostatectomy, the results for these
treatments will be different than those presented. For distant
prostate cancer, we assumed that treatment has no effect. Some
treatments might increase survival of distant disease slightly.
However, in our view this is a minor limitation of the model.
The effect of early detection through screening on survival was
included by assuming that a fraction of local–regional tumours
detected by screening are cured because the tumours are treated
earlier. The Gleason score-dependent cure rates were estimated by
calibrating the ERSPC-Rotterdam model to the observed 29%
prostate cancer mortality reduction in the overall ERSPC at a
median follow-up of 11 years (Schroder et al, 2012).
Analysis. For the present study, we constructed a model in which
individuals were initially screened between the ages of 50 and 74
years, and then subsequently every 4 years until the age of 75 years.
Two situations were simulated: one in which all men with screen-
detected prostate cancer received treatment immediately after
diagnosis; and another in which they received delayed treatment,
that is, they received treatment at the time they would have if
clinically diagnosed in the absence of screening. Comparing these
two simulated populations, life-years gained, reduced probability of
death from prostate cancer, lead time and probability of over-
diagnosis were calculated and stratified according to the prognostic
factors clinical T-stage, Gleason score, and patient age. Note that
lead time is the period by which diagnosis is advanced due to
screening; therefore, mean lead time shows the average potential
life-years with no side effects of treatment in case treatment was
delayed to the time of clinical diagnosis.
Two alternative harm–benefit ratios were subsequently calcu-
lated from the results: the ratio between the mean lead time and
mean life-years gained (M, which represents the average loss of
life-years free from the potential side effects of curative treatment
per life year gained), and the ratio between the percentage of
overdiagnosis and the percentage of prostate cancer deaths
prevented by early treatment (NNT, which represents the
additional number of patients who must be treated in order to
avoid one prostate cancer death). Considering that the decision to
treat immediately or not depends on the variable M, we
determined for which combinations of prognostic factors it would
be less favourable (M49), more favourable (3pMo9), and most
favourable (Mp3) to treat immediately. The ranges for these three
groups were chosen arbitrarily.
Sensitivity analyses. To evaluate the statistical variation and
uncertainty of the observed data, we conducted a number of
sensitivity analyses. The sensitivity analyses compared models with
various lead times, survival curves, and cure rates. Penalised
optimisation was used to obtain a range of models with various
lead times. Parameters for these models were estimated by
minimising the sum of total deviance and lead time penalty (mean
lead time penalty). Different survivals were considered by
assuming a relative risk of 0.8, 1, or 1.2 on the hazard of prostate
cancer death. We also varied assumed mortality reductions due to
screening: 21% (observed for the screen group in ERSPC), 29%
(observed for attendees in ERSPC), or 44% (observed for the screen
group in ERSPC-Gothenburg).
RESULTS
Values describing the potential benefits and harms of active
treatment varied considerably between the different prognostic
groups: mean lead time ranged from 2.9 to 12.2 years; mean life-
years gained ranged from 0.1 to 4.0 years; the percentage of screen-
detected cases that were overdiagnosed ranged from 2.7 to 60.1%;
and the percentage of men who avoided death from prostate cancer
ranged from 1.5 to 32.1% (Table 2).
To illustrate Table 2, consider the example of men with the
following prognostic factors: diagnosed with T1G7 prostate cancer
at 62 years of age. These men each have a 28.4% risk of being an
overdiagnosed case. The mean lead time for such overdiagnosed
men is 11.3 years, that is, if these men decide to be treated at the
time of screen detection they will live an average of 11.3 years with
the potential side effects of curative treatment. The non-over-
diagnosed men have to live an average of 8.5 years with the
potential side effects if they decide to be treated immediately. The
life expectancy is 16.5 years and there is an 18.7% risk of dying
from prostate cancer if the cancer is treated immediately. If the
cancer is treated at the expected time of clinical diagnosis then
their life expectancy is 15.3 years (1.2 years less) and the risk of
dying from prostate cancer is 32.3% (an increase of 13.6% in
absolute terms). The negative effect of treating cancer at screen
detection instead of time of clinical diagnosis is that the patient has
to live on average 9.3 years (((11.3 28.4)þ (8.5 71.6))/100)
longer with the potential side effects of treatment. The positive
effect is that the patient’s life expectancy is 1.2 years longer. The
ratio between the negative effect and the positive effect is 8.0 (the
ratio is not exactly 9.3/1.2 because of rounding of decimals). The
negative effect can also be expressed as the percentage of
overdiagnosed cases (28.4%) and the positive effect as the
percentage of prostate cancer death avoided by treating early
(13.6%). The ratio between these is the NNT (2.1 in this example).
Lower values for these ratios imply lower expected negative effects
in relation to the expected positive effects, and therefore immediate
treatment is more favoured.
The two harm–benefit ratios (M and NNT) also showed
considerable variation between the different prognostic groups:
M ranged from 1.8 to 31.2 and NNT ranged from 0.3 to 11.6
(Table 2). If the same age groups were compared, immediate
treatment was increasingly favourable with increasing Gleason
score for patients at clinical stage T1 or T2. In contrast,
favourability decreased with increasing Gleason score for patients
in same age group at clinical stage T3. Favourability of immediate
treatment increased with increasing T score in patients of the same
age and with a Gleason scoreo7. In patients of the same age, with
a Gleason score of 7, immediate treatment was most favourable in
those with clinical stage T2, followed by stage T3, and then stage
T1. In patients of the same age with a Gleason score 47,
immediate treatment was also most favourable in patients with
clinical stage T2 (although ratios were only slightly lower
compared with T1) and least favourable in T3.
Considering that the decision to treat immediately depends on
the lead time divided by the life-years gained (M), the relationship
between these two variables was plotted in order to better illustrate
how the various combinations of prognostic factors influence the
favourability of immediate treatment after screen detection
(Figure 1). For all age groups, the same pattern can be observed,
where immediate treatment was most favourable in men diagnosed
with T3G6, and least favourable in men diagnosed with T1G6 or
T3G8. The figure illustrates clearly that both the benefits and
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Table 2. Predicted percentage of overdiagnosis,a mean lead time,b life expectancy,c and percentage of prostate cancer (PC) deathd according to
prognostic factors of clinical T-stage, Gleason score, and patient age
Mean lead time
(years)
Treatment at screen-
detection
Treatment at symptoms
presentation
Me NNTe
Clinical
T-stage
Gleason
score
Age at
diagnosis
(years)
Over-
diagnosis
(%)
Over-
diagnosed
Non-
over-
diagnosed
Life
expectancy
(years)
PC
death
(%)
Life
expectancy
(years)
PC
death
(%)
Mean lead
time/mean
life-years
gained
Overdiagnosis/
D PC death
T1 o7 55–59 30.5 15.7 10.7 21.2 9.2 19.7 26.3 7.8 1.8
60–64 39.9 13.4 9.5 17.6 6.5 16.7 18.7 12.1 3.3
65–69 49.8 11.2 8.3 14.2 4.4 13.7 12.7 18.8 6.0
70–74 60.1 8.9 6.9 10.9 2.8 10.7 8.0 30.4 11.6
7 55–59 19.0 12.6 9.0 19.3 26.1 17.2 45.4 4.8 1.0
60–64 28.4 11.3 8.5 16.5 18.7 15.3 32.3 8.0 2.1
65–69 39.0 9.8 7.7 13.6 12.3 13.0 21.4 13.6 4.3
70–74 50.1 7.9 6.7 10.7 7.4 10.4 12.9 24.3 9.2
47 55–59 5.4 6.3 4.8 16.1 47.3 14.1 62.7 2.5 0.4
60–64 9.9 6.4 4.8 14.3 37.6 13.1 49.2 4.3 0.9
65–69 17.4 6.4 4.8 12.4 26.0 11.7 34.3 7.7 2.1
70–74 26.6 5.5 4.4 10.0 17.6 9.6 23.1 13.1 4.8
T2 o7 55–59 18.7 12.5 9.0 20.2 17.4 17.4 43.5 3.5 0.7
60–64 27.9 11.2 8.5 17.0 13.0 15.4 32.2 5.7 1.5
65–69 38.1 9.7 7.6 13.8 9.1 12.9 22.7 9.2 2.8
70–74 49.3 7.9 6.6 10.8 6.0 10.3 14.9 14.9 5.5
7 55–59 9.2 9.7 5.8 16.8 42.2 14.6 60.9 2.7 0.5
60–64 15.0 8.6 5.8 14.9 32.7 13.4 47.8 4.2 1.0
65–69 24.1 8.0 5.6 12.7 23.2 11.8 33.7 7.5 2.3
70–74 34.5 6.8 4.9 10.2 15.1 9.8 22.0 13.5 5.0
47 55–59 4.0 5.1 3.6 12.5 67.4 11.1 77.4 2.6 0.4
60–64 6.5 4.2 3.6 11.6 57.0 10.7 65.5 3.8 0.8
65–69 11.6 4.6 3.9 10.5 44.7 10.0 51.2 7.0 1.8
70–74 21.1 4.7 3.8 9.0 31.3 8.7 35.9 12.8 4.5
T3 o7 55–59 10.6 9.0 7.0 17.7 34.2 13.7 66.3 1.8 0.3
60–64 17.7 8.5 6.9 15.3 27.5 12.8 53.4 2.8 0.7
65–69 26.9 7.9 6.5 12.9 20.4 11.4 39.5 4.7 1.4
70–74 38.3 6.7 5.8 10.3 13.6 9.5 26.5 8.1 3.0
7 55–59 6.7 7.1 5.2 13.1 65.0 11.5 76.3 3.4 0.6
60–64 11.3 6.7 5.2 12.1 55.1 11.1 64.7 5.2 1.2
65–69 18.8 6.6 5.1 10.8 43.1 10.2 50.5 8.8 2.6
70–74 28.8 5.8 4.7 9.1 30.3 8.8 35.5 15.0 5.5
47 55–59 2.7 4.1 2.9 9.0 84.0 8.5 86.6 6.5 1.1
60–64 4.6 3.5 2.9 8.7 76.0 8.5 78.2 10.7 2.1
65–69 9.0 3.7 3.1 8.4 63.8 8.2 65.5 19.0 5.2
70–74 15.5 3.9 3.2 7.6 48.9 7.5 50.4 31.2 10.5
Results describe men diagnosed at the local–regional stage of prostate cancer.
aOverdiagnosis: proportion of men with screen-detected prostate cancer who, in the absence of screening, would die from other causes before the time of clinical diagnosis.
bLead time: interval from time of screen detection to time of clinical diagnosis in the absence of screening (for non-overdiagnosed) or to time of death (for overdiagnosed).
cLife expectancy: mean interval from screen-detection to time of death.
dPercentage of prostate cancer death: proportion of men with screen-detected prostate cancer who die from prostate cancer.
eRatios presented may differ slightly from values calculated using the estimates presented in the table due to the rounding of decimals within the model.
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harms decrease with increasing age, and that the benefits decrease
relatively more than the harms. Therefore, immediate active
treatment after screen detection was less favourable with increasing
age. It also shows that with increasing age there is less variation in
the harms and benefits between the different prognostic groups.
Varying lead time, survival, and mortality reduction caused the
minimum of the harm–benefit ratio M to vary from 1.2 to 2.4 and
the maximum to vary from 20.3 to 44.0 (Table 3). Considering the
different assumptions in the sensitivity analysis, the same pattern
was preserved where immediate treatment was most favourable in
men diagnosed at age 55–59 with T3G6, and least favourable in
men diagnosed at age 70–74 with T1G6 or T3G8.
DISCUSSION
The results from our model demonstrate that, in addition to
potential life-years gained and probability of avoiding death from
prostate cancer, the decision of whether a patient should receive
immediate treatment or not should also depend on the potential
lead time and the probability of overdiagnosis. Our model predicts
that these factors vary considerably depending on the prognostic
factors of clinical T-stage, Gleason score, and patient age.
The two harm–benefit ratios were lowest for men aged 55–59
years, and so immediate treatment would seem most favourable for
this group. Both ratios were lowest for men with moderate-risk
cancer, specifically those diagnosed with T3G6 (representing 3% of
screen-detected cases at 55–59 years of age), T2G7 (7% of screen-
detected cases at 55–59 years of age), T1G8 (1% of screen-detected
cases at 55–59 years of age), and T2G8 (2% of screen-detected
cases at 55–59 years of age). Our model suggests that patients with
these prognostic factors would be likely to derive greatest benefit
from immediate treatment. The majority of men aged 60–69 years
at the time of detection belong to a group for which the harm–
benefit ratios could be considered ‘intermediate’. Men aged 70–74
years with low-risk cancer (T1G6) or high-risk cancer (T3G8) had
the highest ratios and, therefore, immediate treatment is least
favourable for these patients. Indeed, the harm–benefit ratios are
relatively high for all combinations of clinical T-stage and Gleason
score in patients aged 70–74 years, which is due to the low
probability of these patients living long enough to experience the
benefit of curative treatment. The high harm–benefit ratios for
immediate treatment of men aged 70–74 years also imply that the
harm–benefit ratio for the screening of these men will also be high
relative to younger men. Therefore, the negative impact of the
screening process may be reduced by only screening younger men.
Our results suggest that it is crucial to precisely determine which
age groups would derive greatest benefit from screening and at
what age it would be most favourable to cease.
In our models, the harm–benefit ratio is unfavourable in
patients with either favourable prognostic factors or with
unfavourable characteristics. In the first group, this is due to the
extended lead times, in the second group due to the very modest
benefits of immediate treatment. For the first group, patients with
T1G6, T2G6, or T1G7 tumours, active surveillance might allow
treatment to be delayed without impairing the chances of cure too
much. For the second group, patients with T2G8, T3G7, or T3G8
tumours, watchful waiting, that is, waiting for symptoms to appear
and starting palliative treatment when necessary, might be the
most appropriate treatment.
In our analysis, we assumed that the favourability of immediate
treatment for each combination of prognostic factors will depend
on the ratio between mean lead time and mean life-years gained
(M). It is important to note that the three ranges describing the
favourability of the ratio M were chosen arbitrarily and do not
imply that all patients in the least favourable group should not
receive immediate treatment, and that all patients in the most
favourable group should receive immediate treatment. The division
between the groups only illustrates for which combination of
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Figure 1. Comparison of mean life-years gained and mean lead time for different combinations of prognostic factors. The dark grey zone
represents the area where treatment would be considered less favourable (M49), the light grey zone represents the area where treatment would
be considered more favourable (3pMo9), and the white zone represents the area where treatment would be considered most favourable (Mp3).
The variable M is the ratio of the mean lead time to the mean life-years gained, which represents the average loss of life-years free from the
potential side effects of curative treatment per life-year gained.
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prognostic factors it is relatively less favourable to treat
immediately and for which prognostic factors it is relatively more
favourable to treat immediately.
Our modelling study has some limitations. The predicted values
are based on data from a specific population and on the
assumptions underlying the model. However, using the best
available data and most reasonable assumptions, we obtained the
best possible estimates for the measures of interest. The results
were calculated using data from the ERSPC Rotterdam and
Gothenburg. Results may be different for other populations, as
different incidences of and mortalities for prostate cancer have
been observed in different countries (Ferlay et al, 2010). However,
in the appendix of Heijnsdijk et al (2012), it is shown that the
incidence of prostate cancer in the screen arm of all centres of the
ERSPC is predicted well by the model. Also, in the United States,
the estimated lifetime risk of prostate cancer diagnosis is 16.22%
and of prostate cancer death is 2.79% (SEER, 2010), which are close
to lifetime risks of this model (Wever et al, 2012). Therefore, the
results can also be applied in the US population. Another
limitation is that it was not possible to consider all available
prognostic and predictive factors that would be available in clinical
practice. For example, PSA measurements, MRI results, or the
number of positive cores were not considered in our analysis. We
also made no distinction between Gleason scores (3þ 4) and
(4þ 3). These could be important prognostic factors. However, this
is the first study to quantify the benefits and harms of immediate
treatment vs delayed treatment according to the prognostic factors
of clinical T-stage, Gleason score, and patient age. Judging from
our results, it would seem crucial that we understand the impact of
at least these three factors. Another important prognostic factor
that was not included in our model is the presence of co-morbidity.
We suggest that the results obtained for older men in our study
could be considered likely to be similar to individuals with high
levels of co-morbidity. A final limitation is that we used survival
curves based on non-contemporary data observed in the United
States for the ERSPC population that was modelled (Albertsen
et al, 2005). These survival data were used because they are one of
the few data sets presenting survival of untreated prostate cancer as
a function of age at diagnosis and Gleason score progression. The
percentage of prostate cancer death that we report may seem
higher than previous reports (Albertsen et al, 2005; Aus et al, 2005;
Albertsen et al, 2011). However, the percentages of prostate cancer
deaths are generally presented after a follow-up time of 10 or 20
years, whereas our results represent lifetime data. For example,
Albertsen et al (2011) reported that, after 10 years of follow-up, the
percentage of prostate cancer death in men aged 66–75 years and
with T1cG8 is 13.7–25.7%, depending on co-morbidity. In the
present study, the predicted lifetime percentage of prostate cancer
death for men with T1G8 and aged 65–74 is 27.6%; however, the
value is 14.0% after 10-year follow-up, which is on the low side
compared with the numbers reported by Albertsen et al (2011).
In conclusion, the potential benefits and harms of immediate
treatment of local–regional prostate cancer detected by PSA
screening depend on the prognostic factors clinical T-stage,
Gleason score, and patient age. The range of these values by the
different prognostic groups is wide. Therefore, it would seem
important to understand and consider these factors when making
decisions regarding whether or not to treat a patient. Men aged
55–59 years and with moderate-risk cancer (T3G6, T2G7, T1G8, or
T2G8) display the most favourable harm–benefit ratios, and would
therefore seem most likely to derive greatest benefit from
immediate curative treatment. Immediate curative treatment is
least favourable for men aged 70–74 years with low-risk (T1G6) or
high-risk cancer (T3G8).
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Table 3. Sensitivity analysis for uncertainty in the model and the data
M
Mean lead time
Life-years gained
Mean
lead
timea
Relative
risk
on PC
deathb
Mortality
reductionc Minimumd Maximumd
Base model
8.0 1 29% 1.8 (age 55–59,
T3G6)
31.2 (age 70–74,
T3G8)
Varying lead time
8.5 1 29% 2.4 (age 55–59,
T3G6)
37.5 (age 70–74,
T1G6)
7.1 1 29% 1.4 (age 55–59,
T3G6)
25.2 (age 70–74,
T3G8)
Varying survival
8.0 0.8 29% 2.0 (age 55–59,
T3G6)
36.5 (age 70–74,
T3G8)
8.0 1.2 29% 1.7 (age 55–59,
T3G6)
29.0 (age 70–74,
T3G8)
Varying mortality reduction
8.0 1 21% 2.6 (age 55–59,
T3G6)
44.0 (age 70–74,
T1G6)
8.0 1 44% 1.2 (age 55–59,
T3G6)
20.3 (age 70–74,
T3G8)
Abbreviation: PC¼prostrate cancer.
aWe used penalised optimisation to obtain a range of models with different lead times
(Draisma et al, 2003).
bA relative risk of 0.8 on the hazard of prostate cancer death increases PC-specific survival
and a relative risk of 1.2 decreases PC-specific survival.
cWe assumed various mortality reductions: 21% (observed for the screen group in European
Randomized Study of Screening for Prostate Cancer (ERSPC)), 29% (observed for attendees
in ERSPC), or 44% (observed for the screen group in ERSPC-Gothenburg).
dBetween braces is indicated for which age category, clinical T-stage, and Gleason score
the minimum (most favourable) or maximum (least favourable) value belongs to.
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